An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease
Klings E, Machado R, Barst R, Morris C, Mubarak K, Gordeuk V, Kato G, Ataga K, Gibbs J, Castro O, Rosenzweig E, Sood N, Hsu L, Wilson K, Telen M, Decastro L, Krishnamurti L, Steinberg M, Badesch D, Gladwin M. An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal Of Respiratory And Critical Care Medicine 2014, 189: 727-740. PMID: 24628312, PMCID: PMC3983842, DOI: 10.1164/rccm.201401-0065st.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemia, Sickle CellAnticoagulantsAntihypertensive AgentsAntisickling AgentsCardiac CatheterizationDecision Support TechniquesEchocardiography, DopplerErythrocyte TransfusionHumansHydroxyureaHypertension, PulmonaryPhosphodiesterase 5 InhibitorsRisk AssessmentSeverity of Illness IndexConceptsRight heart catheterizationTricuspid regurgitant velocitySickle cell diseasePulmonary vascular resistancePulmonary hypertensionManagement of patientsEvidence-based recommendationsStrong recommendationsWedge pressureVascular resistanceRisk stratificationWeak recommendationCell diseaseMortality riskOfficial American Thoracic Society Clinical Practice GuidelineSerum N-terminal pro-brain natriuretic peptide (NT-proBNP) levelsN-terminal pro-brain natriuretic peptide levelsElevated pulmonary artery wedge pressureNormal pulmonary capillary wedge pressurePro-brain natriuretic peptide levelsElevated tricuspid regurgitant velocityLow pulmonary vascular resistanceNT-pro-BNP levelsPhosphodiesterase-5 inhibitor therapyPulmonary artery wedge pressure